{"title":"Plain language summary of a study testing a new drug (BI 764524) for diabetic macular ischemia.","authors":"Chirag Jhaveri, Daniel Newman, Khaled Nassar","doi":"10.1177/25158414261451676","DOIUrl":null,"url":null,"abstract":"<p><p>What is this summary about? This paper describes the results of a clinical trial called HORNBILL that were published in a scientific journal called Ophthalmology Science. In HORNBILL, researchers looked at a new drug called BI 764524 in the treatment of diabetic macular ischemia (DMI). DMI is a condition that affects people living with diabetes. For people living with DMI, there is reduced blood flow in the center of the retina (an area at the back of the eye that changes light into signals to allow people to see). Reduced blood flow means that the retina does not function correctly and vision can get worse. There are no available treatments for people with DMI, so it is important that research is carried out to find possible new drugs. BI 764524 was injected into the eyes of 33 people with DMI. This paper describes whether there were any safety-related events that might stop BI 764524 being tested in more trials and if it helped people in the trial.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"18 ","pages":"25158414261451676"},"PeriodicalIF":2.0000,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309641/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414261451676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
What is this summary about? This paper describes the results of a clinical trial called HORNBILL that were published in a scientific journal called Ophthalmology Science. In HORNBILL, researchers looked at a new drug called BI 764524 in the treatment of diabetic macular ischemia (DMI). DMI is a condition that affects people living with diabetes. For people living with DMI, there is reduced blood flow in the center of the retina (an area at the back of the eye that changes light into signals to allow people to see). Reduced blood flow means that the retina does not function correctly and vision can get worse. There are no available treatments for people with DMI, so it is important that research is carried out to find possible new drugs. BI 764524 was injected into the eyes of 33 people with DMI. This paper describes whether there were any safety-related events that might stop BI 764524 being tested in more trials and if it helped people in the trial.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
